Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank cohort

New England Journal of Medicine

Volumn 340, Issue 22, 1999, Pages 1715-1722

  Learmont, Jennifer C ^a   Geczy, Andrew F ^a   Mills, John ^b   Ashton, Lesley J ^c   Raynes Greenow, Camille H ^a   Garsia, Roger J ^d   Dyer, Wayne B ^a   McIntyre, Larissa ^a   Oelrichs, Robert B ^b   Rhodes, David I ^b   Deacon, Nicholas J ^b   Sullivan, John S ^a  

^a AUSTRALIAN RED CROSS BLOOD SERVICE   (Australia)

^b MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CD4 ANTIGEN; CYCLOPHOSPHAMIDE; HYDROCORTISONE; PREDNISONE; VIRUS RNA;

ADULT; AGED; ARTICLE; BLOOD DONOR; CLINICAL ARTICLE; FEMALE; FOLLOW UP; GENE DELETION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPATHOLOGY; LABORATORY DIAGNOSIS; LONG TERMINAL REPEAT; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; AGED; AGED, 80 AND OVER; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; FEMALE; GENES, NEF; HIV INFECTIONS; HIV LONG TERMINAL REPEAT; HIV-1; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MUTATION; RNA, VIRAL; VIRAL LOAD;

EID: 0033519616     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199906033402203     Document Type: Article

References (47)

1. Kopec-Schrader E, Tindall B, Learmont J, Wylie B, Kaldor JM. Development of AIDS in people with transfusion-acquired HIV infection. AIDS 1993;7:1009-13.
2. Ashton LJ, Learmont J, Luo K, Wylie B, Stewart G, Kaldor JM. HIV infection in recipients of blood products from donors with known duration of infection. Lancet 1994;344:718-20.
3. Opcrskalski EA, Stram DO, Lee H, et al. Human immunodeficiency virus type 1 infection: relationship of risk group and age to rate of progression to AIDS. J Infect Dis 1995;172:648-55.
4. Muñoz A, Xu J. Models for the incubation of AIDS and variations according to age and period. Stat Med 1996;15:2459-73.
5. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 1996;273:1856-62. [Erratum, Science 1996;274: 1069.]
6. Deng H, Liu R, Ellmeier W, et al. Identification of a major co-receptor for primary isolates of HIV-I. Nature 1996;381:661-6.
7. Kaslow RA, Carrington M, Apple R, et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med 1996;2:405-11.
8. Martin MP, Dean M, Smith MW, et al. Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science 1998;282:1907-11.
9. Kestler HW III, Ringler DJ, Mon K, et al. Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 1991;65:651-62.
10. Kirchhoff F, Greenough TC, Brettler DB, Sullivan JL, Desrosiers RC. Absence of intact nef sequences in a long-term survivor with nonprogres-sive HIV-1 infection. N Engl J Med 1995;332:228-32.
11. Learmont J, Tindall B, Evans L, et al. Long-term symptomless HIV-1 infection in recipients of blood products from a single donor. Lancet 1992; 340:863-7.
12. Gurusinghe AD, Land SA, Birch C, et al. Reverse transcriptase mutants in sequential HIV isolates in a patient with AIDS. J Med Virol 1995;46: 238-43.
13. Deacon NJ, Tsykin A, Solomon A, et al. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 1995;270:988-91.
14. Winkler C, Modi W, Smith MW, et al. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. Science 1998;279:389-93.
15. Smith MW, Dean M, Carrington M, et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Science 1997;227:959-65.
16. Neate EV, Pringle RC, Jowett JBM, Healey DS, Gust ID. Isolation of HIV from Australian patients with AIDS, AIDS related conditions and healthy antibody positive individuals. Aust NZJ Med 1987;17:461-6.
17. Valerie K, Delers A, Brack C, et al. Activation of human immunodeficiency virus type 1 by DNA damage in human cells. Nature 1988;333:78-81.
18. Learmont J, Cook L, Dunckley H, Sullivan JS. Update on long-term symptomless HIV type 1 infection in recipients of blood products from a single donor. AIDS Res Hum Retroviruscs 1995;11:1.
19. Learmont J, Rhodes D, Solomon A, et al. Sydney Blood Bank Cohort (SBBC): additional long term non progressor with HIV (LTNP) identified: immunological update on SBBC 12-15 years post infection. In: Program supplement of the 11th International Conference on AIDS, Vancouver, B.C., July 7-12, 1996:33. abstract.
20. Archer GT, Bolton WV, Cook LA, Learmont JC, Berdoukas V. The apparent failure of triple-washed cell preparations to transmit HIV infection. In: Book 2 of the Proceedings of the Fourth International Conference on Acquired Immune Deficiency Syndrome (AIDS), Stockholm, Sweden, June 12-15, 1988:354. abstract.
21. Fairley CK, Spelman D, Street A, Jennens ID, Spicer WJ, Crowe S. CD4 lymphocyte numbers after splenectomy in patients infected with the human immunodeficiency virus. Int J STD AIDS 1994;5:177-81.
22. Dyer WB, Geczy AF, Kent SJ, et al. Lymphoproliferative immune function in the Sydney Blood Bank Cohort, infected with natural nef/long terminal repeat mutants, and in other long-term survivors of transfusionacquired HIV-1 infection. AIDS 1997;11:1565-74.
23. Muñoz A, Sabin CA, Phillips AN. The incubation period of AIDS. AIDS 1997;11:Suppl A:S69-S76.
24. Hessol NA, Palacio H. Gender, ethnicity and transmission category variation in HIV disease progression. AIDS 1996;10:Suppl A:S69-S74.
25. Leong KH, Boey ML, Feng PH. Coexisting Pneumocystis carinii pneumonia, cytomegalovirus pneumonitis and salmonellosis in systemic lupus erythematosus. Ann Rheum Dis 1991;50:811-2.
26. Porges AJ, Beattie SL, Ritchlin C, Kimberly RP, Christian CL. Patients with systemic lupus erythematosus at risk for Pneumocyitis carinii pneumonia. J Rheumatol 1992;19:1191-4.
27. Learmont J, Sullivan J, Gerrard J. Long term symptomless HIV positive blood transfusion recipients. In; Vol. 2 of the Proceeding: of the 10th International Conference on AIDS, Yokohama, Japan, August 7-12,1994: 254. abstract.
28. Oelrichs R, Tsykin A, Rhodes D, et al. Genomic sequence of HIV type 1 from four members of the Sydney Blood Bank Cohort of long-term nonprogressors. AIDS Res Hum Retroviruses 1998;14:811-4.
29. Greenway AL, Mills J, Rhodes D, Deacon NJ, McPhee D. Serological detection of attenuated HIV-1 variance with nef gene deletions. AIDS 1998;12:555-61.
30. Gibbs JS, Regier DA, Desrosicrs RC. Construction and in vitro properties of SIVmac mutants with deletions in "nonessential" genes. AIDS Res Hum Retroviruses 1994;10:607-16. [Correction of AIDS Res Hum Retroviruses 1994;10:333-42.]
31. Collins KL, Chen BK, Kalams SA, Walker BD, Baltimore D. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature 1998;391:397-401.
32. Miller MD, Warmerdam MT, Gaston I, Greene WC, Feinberg MB. The human immunodeficiency virus-1 nef gene product: a positive factor for viral infection and replication in primary lymphocytes and macrophages. J Exp Med 1994;179:101-13.
33. Spina CA, Kwoh TJ, Chowers MY, Guatelli JC, Richman DD. The importance of nef in the induction of human immunodeficiency virus type 1 replication from primary quiescent CD4 lymphocytes. J Exp Mcd 1994; 179:115-23.
34. Ilyinskii PO, Daniel MD, Simon MA, Lackner AA, Desrosiers RC. The role of upstream U3 sequences in the pathogenesis of simian immunodeficiency virus-induced AIDS in rhesus monkeys. J Virol 1994;68: 5933-44.
35. Greenough TC, Sullivan JL, Desrosiers RC. Declining CD4 T-cell counts in a person infected with nef-deleted HIV-1. N Engl J Med 1999; 340:236-7.
36. Dyer WB, Ogg GS, Demoitie MA, et al. Strong human immunodeficiency virus (HIV-)specific cytotoxic T-lymphocyte activity in Sydney Blood Bank Cohort patients infected with NEF-defective HIV type 1. J Virol 1999;73:436-43.
37. Rosenberg ES, Billingsley JM, Caliendo AM, et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997;278:1447-50.
38. Cameron RG, Black PN, Braan C, Browett PJ. A comparison of the effects of oral prednisone and inhaled beclomethasone dipropionate on circulating leukocytes. Aust N Z J Med 1996;26:800-5.
39. + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997;126:946-54.
40. Ruprecht RM, Baba TW, Liska V. Attenuated HIV vaccine: caveats. Science 1996;271:1790-2.
41. Greenway AL, McPhee DA, Grgacic E, et al. Nef 27, but not the Nef 25 isoform of human immunodeficiency virus-type 1 pNL4.3 down-regulates surface CD4 and IL-2R expression in peripheral blood mononuclear cells and transformed T cells. Virology 1994;198:245-56.
42. Greenway A, Azad A, McPhee D. Human immunodeficiency virus type 1 Nef protein inhibits activation pathways in peripheral blood mononuclear cells and T-cell lines. J Virol 1995;69:1842-50.
43. Desrosieis RC. HIV with multiple gene deletions as a live attenuated vaccine for AIDS. AIDS Res Hum Retroviruses 1992;8:411-21.
44. Idem. Yes, it is time to consider use of a live-attenuated virus vaccine against HIV-1. In: Controversies in science: a live-virus AIDS vaccine? J NIH Res 1994;6:54, 56-9.
45. Proposed live HIV vaccine trials face many problems. Antiviral Agents Bull 1997;10:353-5.
46. Cohen J. Weakened SIV vaccine still kills. Science 1997;278:24-5.
47. Baba TW, Liska V, Khimani AH, et al. Live-attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nat Med 1999;5:194-203.